Status:
COMPLETED
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Gastrointestinal Neoplasms
Ovarian Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with stand...
Detailed Description
Before entering this study the doctor will examine the patient and order blood tests. These tests will use approximately 10 ml of blood. Blood work should be done within 3 weeks prior to treatment.. W...
Eligibility Criteria
Inclusion
- Patients are eligible if they have newly diagnosed histologically confirmed locally advanced or metastatic tumors of the pancreas. Patients must be felt to be unresectable by surgical criteria or felt to be medically inoperable. Patients may also be Stage IV with metastatic disease to the liver. Patients with bone and/or lung metastasis may be included at the investigators discretion.
- Patients must have measurable disease by CT scan.
- Patients must be able to give informed consent. Patients must be older than 18 years of age.
- Patients should have adequate bone marrow, renal, and hepatic function including: Bilirubin less than 1.25 x institutional normal LDH SGPT, SGOT, and alkaline phosphatase less than3 x institutional normal Serum creatinine less than or equal to 3 mg/dl. Absolute neutrophil count of greater than 1500 Hemoglobin greater than 9 gm per dl Platelet count greater than 100,000 WBC greater than 3000 cells per mcl
- Women of child-bearing potential must be agreeable to adequate contraception.(hormonal or barrier method of birth control) prior to study entry and for the duration of study participation.)
- Patients must have a Karnofsky performance status of greater than or equal 60 or Zubrod of less or equal to 2.
- Life expectancy of at least 3 months.
- May have had a second malignancy or multiple malignancies if adequately controlled by clinical means. patients with more than one type of cancer must be cleared by the principal investigator.
- Patients must be at least 1 week from any major operative procedure.
- 10 .Patients may have brain metastasis if these brain metastasis are well controlled by usual clinical criteria and if the life expectancy is at least 3 months. Any patient with brain metastasis must be cleared by the principal investigator.
Exclusion
- Active infection requiring intravenous (IV) antibiotics at the time of entry.
- Cerebral metastasis which has not been adequately controlled.
- Significant malnutrition, cachexia, inundation or inability to give informed consent by clinical assessment.
- Concurrent chemotherapy not prescribed in this protocol.
- Any significant medical problems such as diabetes, cardiomyopathy or hypertension which is not reasonably controlled
- Prior radiation or chemotherapy
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00390182
Start Date
October 1 2003
End Date
May 1 2011
Last Update
March 18 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland & Baltimore VA medical centre
Baltimore, Maryland, United States, 21201
2
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2